Zhang Y, Xia M, Jin K, et al. Function of the c-Met receptor tyrosine kinase in carcinogenesis and associated therapeutic opportunities. Molecular Cancer. 2018;17(1):45. doi:10.1186/s12943-018-0796-y.
Immunohistochemical Expression of “c-MET” in Breast Carcinomas | Open Access Macedonian Journal of Medical Sciences. Published online December 21, 2020. Accessed November 29, 2022. https://oamjms.eu/index.php/mjms/article/view/5070.
Jia L, Yang X, Tian W, Gou S, Huang W, Zhao W. Increased Expression of c-Met is Associated with Chemotherapy-Resistant Breast Cancer and Poor Clinical Outcome. Med Sci Monit. 2018;24:8239-8249. doi:10.12659/MSM.913514.
Liu Y, Yu XF, Zou J, Luo ZH. Prognostic value of c-Met in colorectal cancer: A meta-analysis. World J Gastroenterol. 2015;21(12):3706-3710. doi:10.3748/wjg.v21.i12.3706.
Zhang Z, Miao L, Wang S, et al. Study on the expression of c-Met in gastric cancer and its correlation with preoperative serum tumor markers and prognosis. World Journal of Surgical Oncology. 2022;20(1):204. doi:10.1186/s12957-022-02659-2.
Motwani M, Panchabhai S, Bar J, et al. P60.12 Prevalence of c-Met overexpression (c-Met+) and Impact of Prior Lines of Treatment on c-Met Protein Expression in NSCLC. Journal of Thoracic Oncology. 2021;16(10):S1169-S1170. doi:10.1016/j.jtho.2021.08.633.
Kim JH, Jang HJ, Kim HS, Kim BJ, Park SH. Prognostic impact of high c-Met expression in ovarian cancer: a meta-analysis. J Cancer. 2018;9(19):3427-3434. doi:10.7150/jca.26071.
Based on results from the phase 2 eNRGy trial, the FDA has approved zenocutuzumab for previously treated patients with advanced cholangiocarcinoma harboring NRG1 gene fusions.
Based on results from the phase 2 eNRGy trial, the FDA has approved zenocutuzumab for previously treated patients with advanced cholangiocarcinoma harboring NRG1 gene fusions.
Results from a phase 1/2 study demonstrated that the daraxonrasib showed clinical promise in previously treated patients with RAS-mutated pancreatic ductal adenocarcinoma.
Results from a phase 1/2 study demonstrated that the daraxonrasib showed clinical promise in previously treated patients with RAS-mutated pancreatic ductal adenocarcinoma.
Based on pharmacokinetic bioequivalence data, the FDA has approved extended-release ruxolitinib for patients with myelofibrosis, polycythemia vera, and graft-versus-host disease.
Based on pharmacokinetic bioequivalence data, the FDA has approved extended-release ruxolitinib for patients with myelofibrosis, polycythemia vera, and graft-versus-host disease.
Based on results from the SERENA-6 trial, the FDA’s Oncologic Drugs Advisory Committee has voted that camizestrant plus CDK4/6 inhibition does not demonstrate a favorable benefit-risk profile in patients with HR-positive, HER2-negative...
Based on results from the SERENA-6 trial, the FDA’s Oncologic Drugs Advisory Committee has voted that camizestrant plus CDK4/6 inhibition does not demonstrate a favorable benefit-risk profile in patients with HR-positive, HER2-negative...
Results from a retrospective cohort study demonstrated that completion of consolidative radiotherapy was associated with significantly improved survival outcomes in patients with extensive-stage small cell lung cancer.
Results from a retrospective cohort study demonstrated that completion of consolidative radiotherapy was associated with significantly improved survival outcomes in patients with extensive-stage small cell lung cancer.
Results from a retrospective analysis demonstrated that patterns of post-chemoimmunotherapy progression were strongly associated with outcomes in relapsed small cell lung cancer.
Results from a retrospective analysis demonstrated that patterns of post-chemoimmunotherapy progression were strongly associated with outcomes in relapsed small cell lung cancer.
Results from the phase 2 PREcoopERA trial demonstrated that giredestrant shows antiproliferative activity in premenopausal ER-positive, HER2-negative early breast cancer.
Results from the phase 2 PREcoopERA trial demonstrated that giredestrant shows antiproliferative activity in premenopausal ER-positive, HER2-negative early breast cancer.
Combined results from the JAB-21822-1002 and JAB-21822-1007 trials demonstrate that glecirasib shows clinical promise both alone and in combination with cetuximab in KRAS G12C-mutated locally advanced or metastatic colorectal cancer.
Combined results from the JAB-21822-1002 and JAB-21822-1007 trials demonstrate that glecirasib shows clinical promise both alone and in combination with cetuximab in KRAS G12C-mutated locally advanced or metastatic colorectal cancer.
Exploratory ctDNA results from the phase 2 VALENTINO study demonstrated that baseline detection and early ctDNA dynamics are strongly associated with clinical outcomes in patients with metastatic colorectal cancer.
Exploratory ctDNA results from the phase 2 VALENTINO study demonstrated that baseline detection and early ctDNA dynamics are strongly associated with clinical outcomes in patients with metastatic colorectal cancer.
Based on results from the phase 3 CAPItello-281 trial, the FDA’s Oncologic Drugs Advisory Committee has voted that capivasertib plus abiraterone and ADT demonstrates a favorable benefit-risk profile in PTEN-deficient metastatic...
Based on results from the phase 3 CAPItello-281 trial, the FDA’s Oncologic Drugs Advisory Committee has voted that capivasertib plus abiraterone and ADT demonstrates a favorable benefit-risk profile in PTEN-deficient metastatic...
